Group 1 - The Hong Kong stock market continued its upward trend in September, driven by the resumption of US-China trade negotiations and expectations of overseas interest rate cuts, along with a rotation in the technology sector [1][2] - The external environment is showing marginal improvement, with increased market risk appetite supported by ongoing US-China trade talks and stable macro policies in mainland China [2][3] Group 2 - Liquidity pressure in Hong Kong has eased with the resumption of overseas interest rate cuts, leading to accelerated inflows of southbound capital, with a net inflow exceeding 1.1 trillion HKD this year, setting a new historical high [3] - The market is expected to enter a "quiet season" due to the National Day and Mid-Autumn Festival holidays, alongside uncertainties related to the US government's short-term financing plan, which may amplify overseas disturbances [4] Group 3 - The investment strategy continues to focus on a "high elasticity" and "high dividend" approach, with adjustments based on policy catalysts [5] - In the technology growth sector, the valuation recovery logic for tech stocks is further strengthened under the interest rate cut environment, with strong demand from southbound capital for high-growth sectors like AI [5] - The biopharmaceutical sector is expected to see valuation recovery, with Chinese innovative drug companies accelerating their global expansion [5] - High dividend yielding sectors such as banks, insurance, and utilities are highlighted as stable components in investment portfolios, providing consistent dividend income amid market volatility [5]

Core Insights - The report from CMB International highlights the release of the first batch of innovative pharmaceutical technology medical insurance payment incentive catalog by Zhejiang Province, which is expected to alleviate the challenges of innovative drugs entering hospitals [1] - Despite the Trump administration's announcement of a 100% tariff on imported innovative drugs, the overall impact on China's pharmaceutical industry chain is considered manageable, with a recommendation to monitor subsequent developments [1] - The upcoming ESMO conference in mid to late October is noted as a key event, with a focus on companies such as CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (688331.SH) that are expected to release significant data [1] Industry Summary - The Hong Kong pharmaceutical sector has shown relatively flat performance in September, but with increasing industry catalysts such as academic conferences and favorable policy implementations in October, a market rebound is anticipated [1] - The report recommends focusing on specific segments: 1) Innovative drugs: Companies like 3SBio (01530) and Eucure Biopharma-B (06996) have rich short-term catalysts and their valuations do not yet reflect the core value of major products; companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are considered significantly undervalued with clear long-term growth logic [1] 2) CXO: Leaders in this segment, such as WuXi AppTec (02268), are expected to benefit from high downstream demand and marginal recovery in financing [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 交銀國際控股有限公司 | | | 呈交日期: | 2025年10月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03329 | 說明 | 不適用 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 2,734,392,000 | | 0 | | 2,734,392,000 | | 增加 / 減少 (-) | | ...

Core Viewpoint - The market is expected to enter a "low season" mode due to the impact of the National Day and Mid-Autumn Festival holidays, along with uncertainties surrounding the U.S. government's short-term financing bill and potential overseas disturbances [1] Market Conditions - There is still divergence in the market regarding the timing and extent of interest rate cuts by the Federal Reserve [1] - Some quality sectors in the Hong Kong stock market have valuations close to historical highs, leading to short-term profit-taking pressure [1] Investment Strategy - The company recommends maintaining a "high elasticity" and "high dividend" barbell strategy for industry allocation, with appropriate adjustments based on policy catalysts [1] - Selected stocks for October include: Qifu Technology, Prosperity Industrial Trust (00778), OmniVision Technologies, Kuaishou-W (01024), Alibaba-W (09988), China National Heavy Duty Truck Group (03808), CanSino Biologics (09926), Pop Mart International (09992), and China Power (02380) [1] Sector Insights - Driven by technological narratives, there is a continuous increase in domestic and international computing power investments [1] - The demand from domestic investors for quality Hong Kong stocks in the AI sector remains strong [1]

Core Viewpoint - Aimeson has submitted a listing application to the Hong Kong Stock Exchange, with joint sponsors being CCB International and Bank of Communications International [1] Company Summary - Aimeson is a leading early cancer detection company focused on high incidence and high mortality cancers, having developed a methylation-based early cancer detection technology [1] - The company's core products include Aixin Gan for liver cancer and Aiguang Le for urinary tract cancer, with Aixin Gan being the world's first liver cancer detection reagent based on methylation and qPCR technology, achieving a sensitivity of 84.43% for stage I liver cancer [1] - Aiguang Le allows for non-invasive detection of urinary tract cancer using just 1 milliliter of urine, enhancing efficiency and convenience [1] - Aimeson has a comprehensive early cancer detection platform covering multiple cancers, including colorectal, liver, esophageal, urinary tract, gastric, lung, and gynecological cancers, and is developing several combination detection reagents [1] Industry Summary - The Chinese tumor molecular testing market is rapidly growing, with an expected market size of 38.8 billion RMB by 2033 [1] - Aimeson employs cost-effective qPCR technology combined with proprietary iTBFinder platform, AS-Cap technology, and SEM-PCR technology to enhance detection capabilities [1] - The company is developing an automated sample processing workstation, AMStation, to support large-scale testing [1]

Group 1: Alibaba Group - CMB International maintains a "Buy" rating for Alibaba-SW, raising the target price to HKD 195, citing advancements in AI infrastructure investment of RMB 380 billion and a projected 10x increase in data center energy consumption by 2032 [1] - CICC also maintains an "Outperform" rating for Alibaba-SW, increasing the target price to HKD 197, highlighting the leading position of Tongyi model ecosystem and the potential for commercial value release [1] Group 2: Kuaishou Technology - UBS maintains a "Buy" rating for Kuaishou-W, setting a target price of HKD 95.37, noting significant advancements in the 可灵 2.5 Turbo model for text understanding and video generation [1] Group 3: Xiaomi Corporation - Daiwa Securities maintains a "Buy" rating for Xiaomi Group, with a target price of HKD 76, reporting an increase in weekly electric vehicle deliveries to 10,000-12,000 units and plans to enter the European market by 2027 [2] Group 4: Longwind Pharmaceutical - China Everbright Securities International highlights Longwind Pharmaceutical's strong growth prospects, focusing on inhalation technology and drug development, with six products approved in the respiratory disease field [3] Group 5: Nine Dragons Paper Holdings - Bank of America maintains a "Buy" rating for Nine Dragons Paper, setting a target price of HKD 6.5, with a projected net profit of RMB 1.767 billion for FY25 and a 9.7% increase in sales [3] - Shenwan Hongyuan also maintains a "Buy" rating, noting significant improvements in gross profit and net profit, with expected growth in net profit for 2026-2028 [4] - Guotai Junan raises the target price for Nine Dragons Paper to HKD 7.37, citing a 9.6% increase in sales and a 1.9 percentage point rise in gross margin [4] Group 6: Xindong Company - CMB Securities strongly recommends Xindong Company, highlighting the successful public testing of "伊瑟" and a 37.74% increase in revenue from the TapTap platform [5] Group 7: Mixue Group - CITIC Securities maintains a "Buy" rating for Mixue Group, emphasizing its efficient supply chain and membership growth exceeding 300 million, with plans for expansion in Southeast Asia and new global markets [6]

Core Viewpoint - The Hang Seng Healthcare Index fell by 1.4% this week, underperforming the market, with internet medicine, CXO, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Since September, the proportion of domestic holdings through the Hong Kong Stock Connect has remained stable, while foreign holdings have slightly decreased since mid-year [1] - Both domestic and foreign investors continue to increase their positions in innovative pharmaceutical companies, indicating a consistent long-term strategy [1] Group 2: Investment Recommendations - The report suggests focusing on companies with significant data releases at the upcoming ESMO conference in mid to late October, specifically mentioning Kangfang Biotech (09926), Kelun-Biotech (06990), and Rongchang Biotech (09995) [1] - The importance of timing and stock selection has increased following a broad rise in the innovative drug sector, with recommendations to gradually build positions during market corrections [1] Group 3: Sector Focus - For the innovative drug sector, the report highlights companies such as 3SBio (01530) and Eucure Biopharma-B (06996) as having rich short-term catalysts and undervalued core products, while companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are noted as significantly undervalued with clear long-term growth logic [1] - In the CXO sector, the report points to leading companies benefiting from high downstream demand and marginal recovery in financing, specifically mentioning WuXi AppTec (02268) [1]

Core Viewpoint - The Hang Seng Healthcare Index declined by 1.4% this week, underperforming the market, with internet medicine, CXO, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Since September, the proportion of domestic holdings through the Hong Kong Stock Connect has remained stable, while foreign holdings have slightly decreased since mid-year [1] - Both domestic and foreign investors continue to increase their positions in innovative pharmaceutical companies, indicating a consistent long-term strategy [1] Group 2: Investment Opportunities - Domestic investors are focusing on rebound opportunities, while foreign investors are increasing positions in innovative drug targets with high long-term potential and current cost-effectiveness [1] - The innovative drug guarantee model is gradually taking shape, which is expected to alleviate challenges such as hospital access and reimbursement difficulties for companies [1] Group 3: Upcoming Events - The ESMO conference will be held in mid to late October, and the report suggests focusing on companies like CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (09995) that are expected to release significant data [1] Group 4: Stock Recommendations - The importance of timing and stock selection has increased after a broad rise in the innovative drug sector, with recommendations to gradually build positions during sector pullbacks [1] - Specific recommendations include: 1. Innovative drugs: 3SBio (01530), Eucure Biopharma-B (06996) with rich short-term catalysts and undervalued long-term growth logic [1] 2. CXO: Leaders in high-demand segments benefiting from improved financing conditions, such as WuXi AppTec (02268) [1]

格隆汇9月25日丨交银国际(03329.HK)宣布，伊莉于2025年9月27日起辞任公司公司秘书及公司授权代 表。同日宣布，曾佳荔已获委任为公司公司秘书及授权代表，自2025年9月27日起生效。 ...

曾佳荔女士已获委任为公司公司秘书及授权代表，自2025年9月27日起生效。 交银国际(03329)发布公告，伊莉女士于2025年9月27日起辞任公司公司秘书及公司授权代表(根据香港联 合交易所有限公司证券上市规则第3.05条规定)。 ...